Congress moves to cap drug prices nationwide using international benchmarks
S. 1753 — End Price Gouging for Medications Act · Filed by Jeff Merkley (D-OR) · 3 cosponsors · Introduced May 14, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the HHS Secretary to set annual 'reference prices' for prescription drugs based on the lowest price charged in 12 wealthy countries (Australia, Canada, UK, etc.). Federal health programs—Medicare, Medicaid, VA, TRICARE, and others—cannot pay more than that reference price. Drug manufacturers must also offer the same price to uninsured and privately insured individuals. Manufacturers who refuse face civil penalties of 5 times the overcharge amount; collected penalties fund NIH drug research.
Why we flagged it
The bill's core mechanism is a price ceiling tied to international benchmarks, enforced through civil penalties and applied across federal and private markets. It is fundamentally a price-control measure, not a subsidy, tax, or deregulation.
What the text implies
- The bill applies reference prices to ALL purchasers (uninsured, privately insured), not just federal programs—this is a de facto price control on the entire U.S. drug market, far broader than the title suggests.
- Manufacturers may respond by reducing R&D investment, delaying new drug launches, or withdrawing from the U.S. market—the bill does not address supply-side consequences.
- The Secretary's discretionary authority under subsection (b)(1)(B) to set prices for drugs unavailable in 3+ reference countries is broad and may invite litigation over 'appropriate price' methodology.
- Penalties are calculated on federal program revenue only, but the price ceiling applies to all sales—manufacturers face asymmetric incentives (penalty on federal sales, price cap on all sales).
- The bill does not define 'retail list price' or address rebates, discounts, and negotiated rates already embedded in federal programs—interaction with existing Medicare negotiation authority (IRA) is unclear.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Ordinary citizens—particularly Medicare/Medicaid enrollees, veterans, federal employees, and uninsured individuals—gain direct access to lower drug prices. The bill extends the reference price to all purchasers, not just federal programs, reducing out-of-pocket costs across the board. The enforcement mechanism (5× penalty) creates strong incentive for compliance.
Who stands to gain
- Medicare beneficiaries
- Medicaid enrollees
- Veterans (VA)
- TRICARE beneficiaries
- Federal employees
- Uninsured individuals
- Privately insured individuals
- National Institutes of Health (via penalty transfers)
Named in the bill
HHS Secretary, Drug manufacturers, Medicare, Medicaid, TRICARE, Department of Veterans Affairs, Federal Employees Health Benefits Program, Indian Health Care Improvement Act, National Institutes of Health, Australia, Austria, Belgium, Canada, France, Germany, Italy, Japan, Netherlands, Sweden, Switzerland
Where it stands
3 cosponsors: 2 Democrats, 1 Independents.
- May 14, 2025 — Introduced · Congress.gov: “Introduced in Senate”
- May 14, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
7 lobbying clients named this bill on 15 disclosure filings across 7 quarters, Mar 2025 to Sep 2026. Those filings disclosed $2,386,166 in lobbying spend. A filing names 9 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 83% of bills with at least one filing.
Jeff Merkley, the sponsor, reported $558,525 in PAC receipts in the 2026 cycle.
- Grifols Shared Services North America Inc — $2,160,000 on 5 filings
- Public Citizen — $99,800 on 1 filing
- Drug Policy Alliance — $56,366 on 3 filings
- Drug Policy Alliance — $30,000 on 3 filings
- Center for Health and Democracy — $20,000 on 1 filing
Lobbying Disclosure Act filings through Oct 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (4,453 characters) on Sep 26, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 17,910 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Mar 2025 to Sep 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Oct 20, 2026 · page rendered 2026-11-22.
“Congress moves to cap drug prices nationwide using international benchmarks” QuorumCivic. https://share.quorumcivic.app/bill/119/s1753 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.